Edwards Lifesciences Corporation (EW) to Post Q1 2019 Earnings of $1.10 Per Share, Leerink Swann Forecasts
Edwards Lifesciences Corporation (NYSE:EW) – Investment analysts at Leerink Swann issued their Q1 2019 earnings per share estimates for shares of Edwards Lifesciences in a research note issued on Monday. Leerink Swann analyst D. Antalffy expects that the medical research company will post earnings of $1.10 per share for the quarter. Leerink Swann also issued estimates for Edwards Lifesciences’ Q2 2019 earnings at $1.13 EPS and Q3 2019 earnings at $1.08 EPS.
Other research analysts also recently issued reports about the company. SunTrust Banks set a $124.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Canaccord Genuity reaffirmed a “buy” rating and issued a $135.00 price target (down from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. Cowen reaffirmed a “buy” rating and issued a $135.00 price target on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. Seven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $125.53.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.68 earnings per share.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total value of $3,699,605.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Schack Wesley W. Von sold 1,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the completion of the sale, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 172,480 shares of company stock worth $18,548,810. 2.13% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP boosted its stake in Edwards Lifesciences by 594.9% in the 3rd quarter. GSA Capital Partners LLP now owns 22,565 shares of the medical research company’s stock valued at $2,467,000 after buying an additional 19,318 shares in the last quarter. Belpointe Asset Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $354,000. IFM Investors Pty Ltd acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $637,000. Dana Investment Advisors Inc. boosted its stake in Edwards Lifesciences by 772.9% in the 3rd quarter. Dana Investment Advisors Inc. now owns 27,462 shares of the medical research company’s stock valued at $3,002,000 after buying an additional 24,316 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its stake in Edwards Lifesciences by 6.2% in the 3rd quarter. Sterling Capital Management LLC now owns 25,351 shares of the medical research company’s stock valued at $2,771,000 after buying an additional 1,471 shares in the last quarter. 81.63% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/06/edwards-lifesciences-corporation-ew-to-post-q1-2019-earnings-of-1-10-per-share-leerink-swann-forecasts.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.